KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) EPS (Weighted Average and Diluted) (2016 - 2025)

Abbott Laboratories' EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at $1.01 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 80.8% year-over-year to $1.01; the TTM value through Dec 2025 reached $3.72, down 51.31%, while the annual FY2025 figure was $3.72, 51.31% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $1.01 at Abbott Laboratories, up from $0.94 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $5.26 in Q4 2024 and bottomed at $0.59 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.92 (2023), against an average of $1.12.
  • The largest annual shift saw EPS (Weighted Average and Diluted) skyrocketed 478.02% in 2024 before it crashed 80.8% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.11 in 2021, then tumbled by 46.85% to $0.59 in 2022, then skyrocketed by 54.24% to $0.91 in 2023, then soared by 478.02% to $5.26 in 2024, then tumbled by 80.8% to $1.01 in 2025.
  • Per Business Quant, the three most recent readings for ABT's EPS (Weighted Average and Diluted) are $1.01 (Q4 2025), $0.94 (Q3 2025), and $1.01 (Q2 2025).